NeoGenomics, Inc. (NEO)
- Previous Close
15.13 - Open
15.10 - Bid 15.45 x 800
- Ask 15.52 x 300
- Day's Range
14.86 - 15.50 - 52 Week Range
11.03 - 21.22 - Volume
460,130 - Avg. Volume
927,138 - Market Cap (intraday)
1.98B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.66 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.45
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
www.neogenomics.com2,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NEO
Performance Overview: NEO
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEO
Valuation Measures
Market Cap
1.98B
Enterprise Value
2.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.19
Price/Book (mrq)
2.14
Enterprise Value/Revenue
3.61
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.79%
Return on Assets (ttm)
-3.49%
Return on Equity (ttm)
-8.88%
Revenue (ttm)
610.66M
Net Income Avi to Common (ttm)
-84.23M
Diluted EPS (ttm)
-0.66
Balance Sheet and Cash Flow
Total Cash (mrq)
384.83M
Total Debt/Equity (mrq)
65.86%
Levered Free Cash Flow (ttm)
-12.98M
Research Analysis: NEO
Company Insights: NEO
NEO does not have Company Insights